MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients.
OBJECTIVE
The purpose of our study was to describe the MR signal characteristics of histologically proven liver adenomatosis in three patients using gadoxetic acid, a newly developed liver-specific MR contrast agent.


CONCLUSIONS
In all three patients, more than 100 liver adenomas revealed no metabolism of the new liver-specific contrast agent in the delayed phase. Because of absent or strongly reduced intracellular uptake of gadoxetic acid in all adenomas during delayed contrast-enhanced series, differentiation of adenomas from dysplastic or malignant lesions was not possible.
Giovanoli
Olivier
O
Department of Radiology, University Hospital Basel, Basel, Switzerland. olivier.giovanoli@ksa.ch
Heim
Markus
M
Terracciano
Luigi
L
Bongartz
Georg
G
Ledermann
Hans P
HP
D000236:Adenoma / Q000473:pathology*; D000328:Adult; D003287:Contrast Media; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged
D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D019786:Gadolinium DTPA